Skip to main content

Table 2 Characteristics [mean (SD) or n (%)] of the study population (n = 1934)

From: Coronary heart disease and mortality following a breast cancer diagnosis

 Total (n = 1934)CHD(n = 664)Death (n = 374)
Age (years)
 Mean (SD)58.5 (12.9)62.9 (13.1)61.4 (13.9)
 20–40135 (7.0)23 (3.5)23 (6.1)
  > 40–60975 (50.4)260 (39.2)159 (42.5)
  > 60–100824 (42.6)381 (57.4)192 (51.3)
Race
 Black435 (22.5)209 (31.5)126 (33.7)
 Non-black1419 (73.4)433 (65.2)226 (60.4)
 Unknown80 (4.1)22 (3.3)22 (5.9)
BMI (kg/m2)21.9 (13.6)29.3 (8.3)28.1 (10.1)
Systolic blood pressure (SBP, mmHg)125.4 (20.7)128.4 (22.0)126.0 (20.7)
Diastolic blood pressure (DBP, mmHg)69.8 (11.2)69.8 (11.6)69.4 (11.4)
Fasting glucose (mg/dL)109.3 (33.3)129.9 (53.6)127.6 (58.3)
Hemoglobin A1c (%)6.94 (1.9)7.05 (1.8)7.45 (2.3)
Total cholesterol (mg/dL)186.6 (50.3)181.6 (46.6)178.9 (61.0)
Current smoking66 (3.4)51 (7.7)18 (4.8)
Taking antihypercholesterolemia medication367 (19.0)267 (40.2)88 (23.5)
Taking antihypertensive medication461 (23.8)386 (58.1)215 (57.5)
Taking diabetic medications346 (17.9)238 (35.8)138 (36.9)
Classes of potentially cardiotoxic cancer treatmentsa
Total patients (%) receiving treatments341 (17.6)201 (30.3)128 (34.2)
 Anthracyclines6 (1.8)4 (2.0)3 (2.3)
 Hormone therapy87 (25.5)51 (25.4)28 (21.9)
 Aromatase inhibitors158 (46.3)97 (48.3)44 (34.3)
 Monoclonal antibodies7 (2.1)3 (1.5)2 (1.6)
 Antimicrotubule agents15 (4.4)9 (4.5)9 (7.0)
 Alkylating agents21 (6.2)12 (6.0)12 (9.4)
 Antimetabolites37 (10.9)20 (10.0)27 (21.1)
 Other10 (2.9)5 (2.5)3 (2.3)
  1. aThe percentages for each class of treatments used 341, 201 and 128 as the denominator